An observational study in Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome and Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), sponsored by University of British Columbia. Enrolling by invitation at 1 site in Canada. Per ClinicalTrials.gov, last updated 2022-11-03.
Sponsored by University of British Columbia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Death, Sudden, Cardiac with a site in Canada — 6 open to participants now, 8 under way, none of them phase 3. Death, Sudden, Cardiac · Canada.
Among the 26 studies in Death, Sudden, Cardiac with a site in Canada, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2019, is one of 12 observational ones, and was the 21st registered.
364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.
Browse Death, Sudden, Cardiac studies →6 of the 26 studies in Death, Sudden, Cardiac with a site in Canada are open now. Recruiting first, the newest first:
Hamilton Health Sciences Corporation · Sites in Canada
Ages 18+
Unity Health Toronto · Sites in Canada
Ages 18+
Population Health Research Institute · Sites in Canada, United States, Belgium and 4 more countries
Montreal Heart Institute · Sites in Canada
University of California, Los Angeles · Sites in Canada, United States, Israel and 4 more countries
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.
This study: all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 450 across 203 observational studies indexed under Death, Sudden, Cardiac.
Median enrollment 159 across the 14 interventional studies, 7,882 across the 12 observational. Of the 17 that completed or were terminated, 3 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 26 have an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of British Columbia has 3 studies filed under Death, Sudden, Cardiac — fewer than ten, so there is no comparison to draw.
3 of the studies in Death, Sudden, Cardiac with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT06174220Hamilton Health Sciences CorporationTargeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy | 2027-02-01 |
| NCT01114269Brigham and Women's HospitalPRE-DETERMINE Cohort Study | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Death, Sudden, Cardiac with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD).
Canadian adult and pediatric electrophysiology centres across Canada work together to gather data and bio sample in a national data registry and bio bank hoping to improve the detection and treatment of inherited heart rhythm disorders to prevent sudden death.
Led by clinical researchers, HiRO is focused on identifying phenotype-genotype correlations. HiRO has defined the investigation pathway for patients with possible genetically mediated cardiac arrest, and has had major impact on our understanding of familial sudden death. However, because many of the Canadian clinics lack a system of care or embedded research, it is difficult to translate novel discoveries to improved care. This current protocol provides a system wide mechanism to allow the national investigator group to work together more efficiently to ensure the inclusion of all Canadians affected by the inherited causes of SCD to help ensure standardized quality care for this population in all provinces with embedded opportunity for all individuals to participate in research.
Background:
Inherited Heart rhythm disorders include arrhythmogenic right ventricular cardiomyopathy (ARVC), Brugada Syndrome, Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) and Long QT Syndrome (LQTS). They affect one in 200 Canadians and can result in tragic sudden cardiac death (SCD), reduced quality of life and productivity, and high health care expenditure. SCD kills 30,000 Canadians/year. Importantly, clinical screening for at-risk individuals has tremendous potential for timely monitoring and treatment. Treatment typically involves lifestyle modifications, such as avoidance of strenuous exercise, drugs that may worsen the phenotype or medical therapy with beta-blockers or quinidine which can provide substantial protection from SCD. Patients who have cardiac events while on medical therapy, have suffered an unexplained cardiac arrest (UCA), or are deemed sufficiently high risk are offered an implantable cardioverter defibrillator (ICD). ICD therapy provides protection however, it is commonly associated with life-long device related complications.
Patients reviewed in partnering HiRO, Inherited Heart Rhythm Clinics will be invited to participate in the registry.
Optional bio bank participation:
Participants will be invited to provide a blood or saliva sample for storage for future research.Central bio banking for all national bio banks will be available at the lead centre in Vancouver in the James Hogg lab at St. Paul's Hospital in Vancouver BC
Data Collection:
Clinical data will be collected from willing/consented registry participants. Their healthcare information will be coded in compliance with Tri Council Policy Statement criteria: direct identifiers will be removed and replaced with a unique study code that does not use personal information such as the participant's birth day (month and year will be included), health number, social insurance number or name/initials. The coded data will be transferred into the research database.
The master list of registry participants with their study identifiers will be kept separately from the research database. This master list will be stored in an encrypted file within the research office of each site investigators under their supervision. Only the site investigators and their local research staff will have access to this list. The inherited nature of these conditions makes the master list an important and very sensitive document. It will be very important that this list is maintained so that participants may be contacted and informed of any new findings the research may reveal that may affect themselves and their family members.
All medical information pertaining to the cardiac history of inherited arrhythmia patients will be collected. This may include:
Follow-up:
Participants are reassessed as part of clinical care every 3 years in person, collecting the same data as at baseline; this is a repeat phenotyping cycle and reflects standard clinical practice in Canada in the adult IHR population.
Research Data system:
The data base will be maintained by the HiRO research coordinating centre in Vancouver BC. The database will be hosted on the Amazon Virtual Private Network. This network is in compliance with National Canadian/Provincial PIPEDA privacy guidelines. Data will be entered directly into the e-CRFs for electronic submission to a password protected internet-based server located in Montreal Quebec Canada.
Individual participant medical information obtained as a result of this registry is considered confidential and disclosure to third parties is prohibited except for the following reason: relevant medical information may be given to the participant's personal physician or to other appropriate medical personnel responsible for the participant's welfare.
Bio Bank:
Biological (blood or saliva) samples will be coded in compliance with Tri Council Policy Statement criteria: direct identifiers will be removed and replaced with a unique study code that does not use personal information such as the participant's birth date, health care number, social insurance number or name/initials. The coded samples will be linked to the master list kept securely in the research office of the individual investigators. Each sub site investigator and their local research staff will have access to the master list of their local patients only. These master lists will not be shared amongst the investigators.
Blood Samples drawn:
1 X 9 ml EDTA
1 X 10 ml redtop serum tube
Saliva sample: cheek swab
Samples for bio banking will be managed by the coordinating centre in Vancouver British Columbia stored long-term in the James Hogg Research Centre (JHRC) Bio Bank at St. Paul's Hospital in Vancouver for future research.
Oversight
HiRO Research Steering Committee (HRSC) for the National HiRO research registry and bio bank:
The HRSC will be responsible for the design, execution, analysis, and reporting of the study, and will assign appropriate responsibilities to the other study committees. The HRSC will monitor study progress, execution and management. This committee will be responsible for the integrity of the study data and samples. They will also be responsible for reviewing and approving sub study proposals, for use of the registry data and bio samples.
The committee members are:
Dr. Jason Roberts (London Health Sciences) Dr. Andrew Krahn (University of BC/Vancouver) Dr. Rafik Tadros (Montreal Heart Institute) Julia Cadrin -Tourginy (Montreal Heart Institute) Dr. Ciorsti MacIntyre (Dalhousie/Halifax) Dr. Christian Steinberg (Laval/Quebec) Dr. Martin Gardner (Dalhousie/Halifax) Dr. Martin Green (Ottawa Heart Centre)
National HiRO Patient/Public Partners when appropriate will review and advise on projects to provide the patient perspective of the research questions and will propose patient oriented research projects.
Database/bio bank access and Oversight:
The HRSC will have ultimate responsibility for the database. All Investigators on the HRSC listed in this protocol will have equal access to the de-identified data once they have signed the HRSC charter (* see attachment #3*). The HRC investigators will be responsible for annual reviews of data collection, to ensure completeness and accuracy
Proposed sub- studies involve an established proposal submission form, discussion, formal presentation to the HRSC for approval, and a robust lab manual that defines sample access, handling, analysis and reporting.
Only aggregate coded data would be released for these purposes. These data/specimens may be used by a variety of sources. It is anticipated that there may be requests to pool de-identified data/specimens with data/specimens from other international registries/banks in order to answer investigator initiated questions about patient selection, rare events, and long term outcomes.
The registry will include all willing participants seen as patients in the HiRO network that are evaluated for familial risk of sudden death. The registry will include, inheritable heart rhythm conditions including but not restricted to; Brugada Syndrome, Long QT syndrome, hypertrophic cardiomyopathy (HCM), catecholaminergic polymorphic ventricular tachycardia (CPVT), and arrhythmogenic right ventricular cardiomyopathy (ARVC) and uncommon variants of ARVC that are listed fully in the inclusion criteria section of this protocol as well as first degree family members.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Canadian patients referred for cardiac investigations related to inherited heart rhythm (IHR) conditions will be invited to participate if they meet the following criteria:
Mendelian cardiomyopathies (hypertrophic cardiomyopathy (HCM), Mendelian Dilated Cardiomyopathy (DCM) including Lamin and Phosopholambin (LMNA, \& PLN), and Left Ventricular Non -Compaction (LVNC).
**Must have either a probable or definite clinical diagnosis, first degree relative (FDR) with a known diagnosis, gene carrier (disease causing or likely disease causing by American College of Medical Genetics (ACMG 2015), or may be second degree relative (SDR) with inability to screen intervening relative
Exclusion:
Patients referred for cardiac investigations related to inherited heart rhythm conditions will be excluded from participating if they meet the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Create a Canadian Research Data base and Bio bank for those affected by inherited heart rhythm conditions.
To build a data registry and bio bank of 10,000.00 inherited heart rhythm cases
Time frame: November 2019 - June 2025
Plan to share: No
Started Aug 2019 (actual). Primary completion is estimated for Dec 2025, 76 months after the start.
Of 70 non-industry observational studies under Death, Sudden, Cardiac, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 42. This study's planned 76 months is close to that.
Counting every sponsor, half of 86 studies reached it within 63 months; a quarter within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →